

# Anionic [4+3] heteroannulation of 2-azidoacrylates: A modular synthesis of 2-benzazepin-1-ones

Bidyut Kumar Dinda, Amit Kumar Jana and Dipakranjan Mal\*  
Department of Chemistry, Indian Institute of Technology, Kharagpur 721302, India  
*dmal@chem.iitkgp.ernet.in*

## Supporting Information

### List of Contents

1. General Remarks	S2
2. General Procedure of Annulation	S2
3. General Procedure of Oxidation	S2
4. Preparation of azidoacrylates	S3
4(i). General Procedure of the Preparation of azidoacrylate <b>1a</b> and <b>1b</b>	S3
4(ii). Preparation of methyl 2-azido-2-butenate ( <b>1c</b> )	S4
5. Preparation of phthalides	S4
6. Spectrum Data of the new compounds	S4–S15
7. References	S15
8. NMR Spectra of the new compounds	S16–S35
9. X-ray crystal structure of <b>12</b> , <b>3d</b> and <b>3g</b>	S36–S38

## 1. General Remarks:

Melting points were determined in open-end capillary tubes and are uncorrected. Solvents were dried and distilled following the standard procedures. TLC was carried out on precoated plates (silica gel 60, GF254), and the spots were visualized with UV and fluorescent lights. Column chromatography was performed on silica gel (60–120 or 230–400 mesh).  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectra for all the compounds were recorded at 200/400 and 50/100 MHz respectively. IR spectra were recorded on an FT-IR instrument using a KBr pellet.

## 2. General Procedure of Annulation:


To a stirred solution of lithium hexamethyldisilazide (3.2 mmol) in THF (10 mL) at  $-78\text{ }^\circ\text{C}$  under an inert atmosphere was added a solution of phthalide (1 mmol) in THF (5 mL). The resulting yellow solution was stirred at  $-78\text{ }^\circ\text{C}$  for 30 min, after which a solution of a Michael acceptor (1.05 mmol) in THF (5 mL) was slowly added to the mixture. The cooling bath was removed after about 30 min and the reaction mixture was allowed to reach rt over a period of 15 min. Then it was allowed to stir at rt for further 6–7 h. After the completion of reaction (monitored by TLC) the mixture was quenched with 10% aq  $\text{NH}_4\text{Cl}$  (15 mL) and the resulting solution was concentrated under reduced pressure. The residue was extracted with ethyl acetate ( $3 \times 50\text{ mL}$ ) and the organic layer was washed with water ( $3 \times 20\text{ mL}$ ). Finally the resulting organic layer was washed with brine ( $2 \times 20\text{ mL}$ ). Organic layer was collected and dried ( $\text{Na}_2\text{SO}_4$ ), and concentrated. The residue was purified by column chromatography on silica gel to obtain a pure product.

## 3. General Procedure of Oxidation:

To a solution of benzazepinone (1 mmol) in dry chloroform (8 mL), active  $\text{MnO}_2$  (5 mmol) was added and the mixture was allowed to stir at rt for 6–7 h. After completion of reaction (monitored by TLC) the mixture was filtered through a celite bed and concentrated in vacuum. The crude solid product was purified by column chromatography on silica gel to obtain a pure product.

**4. Preparation of azidoacrylates:** Azidoacrylates **1a** and **1b** were prepared by modification of the literature procedure.<sup>1</sup> Azidoacrylates **1d**,<sup>2</sup> **1e–1g**,<sup>3</sup> **1h**,<sup>3,4</sup> **1i**,<sup>3,5</sup> and **1j**<sup>6</sup> were prepared according to the literature procedures.

**4(i). General Procedure of the preparation of azidoacrylates 1a and 1b<sup>1</sup>:**




**Scheme 1:** Synthesis of azidoacrylates **1a** and **1b**

To a solution of methyl acrylate (**23**) or ethyl acrylate (**24**) (58.14 mmol in 25 mL DCM) 58.19 mmol of bromine in 3 mL DCM was added dropwise at 0 °C during 20 min under an inert atmosphere. The reaction mixture was allowed to stir at 0 °C for 1 h and then at rt for overnight. After completion of the reaction, the mixture was quenched with saturated aq Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> solution. Filtration of the mixture followed by extraction of the filtrate with DCM and water and then separation of the organic layer gave the dibromo compound in 90–95% yield.

The dibromo ester (**25** or **26**) (3.0 mmol) was dissolved in DMF and treated with 4.5 mmol of NaN<sub>3</sub> at 60 °C. After 20 min, an additional 3.0 mmol of the NaN<sub>3</sub> was added and the mixture was allowed to stir for further 25 min under the same temperature. After cooling, the reaction mixture at rt, it was extracted with ice cold *n*-pentane and water. Finally, the resulting organic layer was washed with brine. Organic layer was collected and dried (Na<sub>2</sub>SO<sub>4</sub>). Removal of the solvent under reduced pressure and at temperature below 25 °C gave the azidoacrylates in 80–85% yield.

**4(ii). Preparation of methyl 2-azido-2-butenoate (1c):**



**Scheme 2:** Synthesis of methyl 2-azido-2-butenate (**1c**)


Dibromo ester **28** was prepared by bromination of methyl crotonate (**27**) following the procedure 4(i). This was then reacted with sodium azide in the presence of tetrabutylammonium hydrogen sulphate (TBAHS). Treatment of diazido ester **29** with 1.2 equivalent of triethylamine in acetone at rt afforded the elimination product **1c**. The crude was extracted with ether and the organic layer was washed with water. Finally the resulting organic layer was washed with brine. Organic layer was collected and dried ( $\text{Na}_2\text{SO}_4$ ), and concentrated. Silica gel column chromatography of the residue with 10% ethylacetate-petroleum ether gave pure compound **1c**<sup>7</sup> in 90% overall yield for the last two steps.

## 5. Preparation of phthalides:

Phthalide **2a** is commercially available. Phthalide **2b**<sup>8</sup>, **2c**<sup>9</sup>, **2d**<sup>10</sup> and **2e**<sup>11</sup> were prepared according to literature procedure.


## 6. Spectrum Data of new compounds:

**Methyl 5-hydroxy-1-oxo-2,5-dihydro-1H-benzo[c]azepine-3-carboxylate (3a).**




White solid. mp 121–124 °C. IR (KBr):  $\tilde{\nu}$  = 1730, 1633, 1450, 1367, 1265, 1080, 760  $\text{cm}^{-1}$ .  $^1\text{H}$  NMR (200 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.95(brs, 1H), 7.91 (d,  $J$  = 7.6 Hz, 1H), 7.61–7.57 (m, 2H), 7.44–7.35 (m, 1H), 6.64 (d,  $J$  = 5.2 Hz, 1H), 5.37 (d,  $J$  = 5.2 Hz, 1H), 3.81 (s, 3H).  $^{13}\text{C}$  NMR (50 MHz,  $\text{CDCl}_3$ ):  $\delta$  168.5, 163.1, 143.6, 133.0 (CH), 130.9 (CH), 129.2, 128.8 (CH), 127.9 (CH), 125.3, 122.1 (CH), 68.1 (CH), 52.9 ( $\text{CH}_3$ ). HRMS: Found:  $m/z$  256.0584. Calcd for  $\text{C}_{12}\text{H}_{11}\text{NO}_4$ : ( $\text{M} + \text{Na}$ ) $^+$  256.0586.

**Methyl 1,5-dioxo-2,5-dihydro-1*H*-benzo[*c*]azepine-3-carboxylate (4).**




White solid. mp 176–178 °C. IR (KBr):  $\tilde{\nu}$  = 1726, 1700, 1654, 1334, 1280, 774  $\text{cm}^{-1}$ .  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  8.93 (brs, 1H), 8.55 (m, 1H), 8.28 (m, 1H), 7.80 (m, 2H), 6.89 (s, 1H), 4.00 (s, 3H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  187.3, 165.3, 163.8, 137.0, 134.2 (CH), 133.6 (CH), 133.3 (CH), 131.8, 130.7 (CH), 129.9, 114.3 (CH), 54.5 ( $\text{CH}_3$ ).

**Methyl 5-acetoxy-1-oxo-2,5-dihydro-1*H*-benzo[*c*]azepine-3-carboxylate (5).**




White solid, decomposes at high temperature.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  8.23 (brs, 1H), 8.00 (dd,  $J$  = 7.6 Hz, 0.8 Hz, 1H), 7.57 (t,  $J$  = 7.6 Hz, 1H), 7.46 (t,  $J$  = 8.0 Hz, 1H), 7.38 (d,  $J$  = 7.6 Hz, 1H), 6.66 (dd,  $J$  = 6.2 Hz, 1.0 Hz, 1H), 6.29 (d,  $J$  = 6.0 Hz, 1H), 3.82 (s, 3H), 2.15 (s, 3H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  169.9, 168.0, 163.3, 138.7, 133.2 (CH), 131.8 (CH), 130.3, 129.0 (CH), 127.6, 124.3 (CH), 122.8 (CH), 69.8 (CH), 53.3 ( $\text{CH}_3$ ), 21.0 ( $\text{CH}_3$ ).

**Ethyl 5-hydroxy-1-oxo-2,5-dihydro-1*H*-benzo[*c*]azepine-3-carboxylate (3b).**




White solid. mp 105–108 °C. IR (KBr):  $\tilde{\nu}$  = 1718, 1639, 1465, 1354, 1261, 1143, 1020  $\text{cm}^{-1}$ .  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  8.09 (s, 1H), 7.82 (d,  $J$  = 7.6 Hz, 1H), 7.54 (m, 2H), 7.33 (m, 1H), 6.60 (d,  $J$  = 4.8 Hz, 1H), 5.05 (d,  $J$  = 4.8 Hz, 1H), 4.22 (q,  $J$  = 14.4 Hz, 7.2 Hz), 1.27 (t,  $J$  = 7.2 Hz, 3H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  169.2, 162.8, 144.1, 133.2 (CH), 130.7 (CH), 130.0 (CH), 128.7, 127.9 (CH), 125.3, 122.3 (CH), 68.1 (CH), 62.4 ( $\text{CH}_2$ ), 14.3 ( $\text{CH}_3$ ).

**Methyl 5-hydroxy-4-methyl-1-oxo-2,5-dihydro-1H-benzo[*c*]azepine-3-carboxylate (3c).**




White solid. mp 162 °C. IR (KBr):  $\tilde{\nu}$  = 1714, 1637, 1377, 1315, 1219  $\text{cm}^{-1}$ .  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.88 (d,  $J$  = 7.6 Hz, 1H), 7.85 (brs, 1H), 7.58 (d,  $J$  = 4.4 Hz, 2H), 7.41–7.37 (m, 1H), 5.51 (s, 1H), 3.80 (s, 3H), 2.24 (s, 3H).

**Methyl 4-methyl-1,5-dioxo-2,5-dihydro-1H-benzo[*c*]azepine-3-carboxylate (12).**




Colorless crystal. mp 152 °C. IR (KBr):  $\tilde{\nu}$  = 1726, 1700, 1654, 1334, 1280, 1016, 774  $\text{cm}^{-1}$ .  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  8.51 (brs, 1H), 8.27 (m, 1H), 7.73 (m, 3H), 3.96 (s, 3H), 2.33 (s, 3H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  195.2, 165.9, 164.4, 139.3, 134.0 (CH), 133.0 (CH), 131.5 (CH), 129.3 (CH), 129.2, 129.1, 128.0, 53.8 ( $\text{CH}_3$ ), 16.8 ( $\text{CH}_3$ ).

**Methyl 4-methyl-1-oxo-2,3,4,5-tetrahydro-1*H*-benzo[*c*]azepine-3-carboxylate (13).**




White solid. mp 110–112 °C. IR (KBr):  $\tilde{\nu}$  = 1730, 1629, 1450, 1240, 1150, 728  $\text{cm}^{-1}$ .  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.70 (d,  $J$  = 7.2 Hz, 1H), 7.42 (t,  $J$  = 7.2 Hz, 1H), 7.35 (t,  $J$  = 7.2 Hz, 1H), 7.21 (d,  $J$  = 7.6 Hz, 1H), 6.66 (brs, 1H), 3.99 (t,  $J$  = 4.8 Hz, 1H), 3.76 (s, 3H), 2.80 (m, 1H), 2.59 (d,  $J$  = 11.2 Hz, 2H), 0.94 (d,  $J$  = 6.0 Hz, 3H). [Decoupling experiment by irradiation of the 'NH' proton revealed the coupling constant between  $\text{CHCO}_2\text{Me}$  and  $\text{CHCH}_3$  to be 4.0 Hz, which conformed to the *cis* stereochemistry of benzazepinone **15**].  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  171.4, 171.2, 137.9, 134.5, 131.7 (CH), 129.1 (CH), 129.0 (CH), 127.6 (CH), 57.1 (CH), 52.8 (CH<sub>3</sub>), 39.7 (CH), 39.2 (CH<sub>2</sub>), 15.3 (CH<sub>3</sub>). HRMS: Found:  $m/z$  234.1124. Calcd for  $\text{C}_{13}\text{H}_{16}\text{NO}_3$ :  $(\text{M} + \text{H})^+$  234.1130.

**Methyl 5-hydroxy-1-oxo-4-phenyl-2,5-dihydro-1*H*-benzo[*c*]azepine-3-carboxylate (3d).**




Colorless crystal. mp 150–154 °C. IR (KBr):  $\tilde{\nu}$  = 1708, 1654, 1260, 1204, 752  $\text{cm}^{-1}$ .  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  8.08 (s, 1H), 7.96 (d,  $J$  = 7.6 Hz, 1H), 7.58 (dd,  $J$  = 7.6 Hz, 7.2 Hz, 1H), 7.44 (t,  $J$  = 7.6 Hz, 1H), 7.38 (m, 4H), 7.00 (brs, 2H), 5.63 (s, 1H), 3.49 (s, 3H). HRMS: Found:  $m/z$  310.1074. Calcd for  $\text{C}_{18}\text{H}_{16}\text{NO}_4$ :  $(\text{M} + \text{H})^+$  310.1079.

**Methyl 1,5-dioxo-4-phenyl-2,5-dihydro-1*H*-benzo[*c*]azepine-3-carboxylate (14).**



White solid. mp 194–195 °C. IR (KBr):  $\tilde{\nu}$  = 1736, 1707, 1618, 1382, 1262, 1012, 760. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  8.43 (brs, 1H), 8.37 (m, 1H), 7.78 (m, 3H), 7.36 (m, 3H), 7.24–7.21 (m, 2H), 3.51 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$  192.3, 166.0, 165.2, 140.0, 135.9, 134.3 (CH), 133.2, (CH), 131.9 (CH), 130.3, 129.6 (CH), 129.5 (CH), 129.1, 128.4 (CH), 128.3 (CH), 53.5 (CH<sub>3</sub>).


**Methyl 5-hydroxy-4-(4-methoxy-phenyl)-1-oxo-2,5-dihydro-1H-benzo[c]azepine-3-carboxylate (3e).**



White solid. mp 144–146 °C. IR (KBr):  $\tilde{\nu}$  = 1708, 1654, 1248, 1178, 1034, 752 cm<sup>-1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  8.04 (brs, 1H), 7.98 (d, *J* = 7.6 Hz, 1H), 7.58 (t, *J* = 7.6 Hz, 1H), 7.44 (t, *J* = 7.6 Hz, 1H), 7.38 (d, *J* = 7.2 Hz, 1H), 6.91 (m, 4H), 5.67 (d, *J* = 4.4 Hz, 1H), 3.83 (s, 3H), 3.54 (s, 3H), 2.22 (d, *J* = 5.2 Hz, 1H, –OH proton, D<sub>2</sub>O exchangeable).


**Methyl 4-(4-methoxy-phenyl)-1,5-dioxo-2,5-dihydro-1H-benzo[c]azepine-3-carboxylate (15).**






White solid. mp 212–214 °C. IR (KBr):  $\tilde{\nu}$  = 1740, 1719, 1628, 1384, 1250, 928, 554  $\text{cm}^{-1}$ .  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  8.42 (brs, 1H), 8.35 (m, 1H), 7.77 (m, 3H), 7.16 (d,  $J$  = 8.2 Hz, 2H), 6.89 (d,  $J$  = 8.2 Hz, 2H), 3.83 (s, 3H), 3.56 (s, 3H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  192.9, 165.9, 165.4, 159.8, 140.1, 134.3 (CH), 133.2 (CH), 131.8 (CH), 130.8 (CH), 130.2, 129.8, 129.5 (CH), 129.1, 127.9, 113.8 (CH), 55.5 ( $\text{CH}_3$ ), 53.6 ( $\text{CH}_3$ ).

**Methyl 5-hydroxy-1-oxo-4-p-tolyl-2,5-dihydro-1H-benzo[c]azepine-3-carboxylate (3f).**




White solid. mp 136 °C. IR (KBr):  $\tilde{\nu}$  = 1709, 1640, 1262, 1044, 754  $\text{cm}^{-1}$ .  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  8.09 (s, 1H), 7.94 (d,  $J$  = 7.6 Hz, 1H), 7.56 (m, 1H), 7.43–7.37 (m, 2H), 7.16 (d,  $J$  = 8.0 Hz, 2H), 6.89 (brs, 2H), 5.58 (s, 1H), 3.51 (s, 3H), 2.37 (s, 3H).

**Methyl 1,5-dioxo-4-p-tolyl-2,5-dihydro-1H-benzo[c]azepine-3-carboxylate (16).**




White solid. mp 220–222 °C. IR (KBr):  $\tilde{\nu}$  = 1735, 1710, 1664, 1364, 1280, 950, 742  $\text{cm}^{-1}$ .  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  8.49 (brs, 1H), 8.35 (m, 1H), 7.76 (m, 3H), 7.17 (d,  $J$  = 7.6 Hz, 2H), 7.11 (d,  $J$  = 8.0 Hz, 2H), 3.55 (s, 3H), 2.37 (s, 3H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  192.7, 166.0, 165.2, 140.3, 138.3, 134.2 (CH), 133.1 (CH), 132.8, 131.8 (CH), 130.5, 129.9, 129.5 (CH), 129.4 (CH), 129.1 (CH), 53.5 ( $\text{CH}_3$ ), 21.5 ( $\text{CH}_3$ ) [N.B. one quaternary C is missing].

**Methyl 4-(4-chloro-phenyl)-5-hydroxy-1-oxo-2,5-dihydro-1H-benzo[c]azepine-3-carboxylate (3g).**



Colorless crystal. mp 168 °C. IR (KBr):  $\tilde{\nu}$  = 1736, 1630, 1258, 1090, 754  $\text{cm}^{-1}$ .  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  8.08 (s, 1H), 7.94 (d,  $J$  = 7.6 Hz, 1H), 7.58 (t,  $J$  = 7.6 Hz, 1H), 7.44 (t,  $J$  = 7.6 Hz, 1H), 7.37 (d,  $J$  = 6.4 Hz, 1H), 7.32 (d,  $J$  = 8.0 Hz, 2H), 6.94 (brs, 2H), 5.56 (s, 1H), 3.52 (s, 3H), 2.74 (brs, 1H, -OH proton).


**Methyl 4-(4-chloro-phenyl)-1,5-dioxo-2,5-dihydro-1H-benzo[c]azepine-3-carboxylate (17).**



White solid. mp 218 °C. IR (KBr):  $\tilde{\nu}$  = 1742, 1705, 1620, 1218, 1020, 772  $\text{cm}^{-1}$ .  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  8.58 (s, 1H), 8.37 (d,  $J$  = 7.2 Hz, 1H), 7.78 (m, 3H), 7.34 (d,  $J$  = 8.0 Hz, 2H), 7.17 (d,  $J$  = 8.0 Hz, 2H), 3.57 (s, 3H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  191.8, 165.9, 164.9, 139.7, 134.6, 134.4 (CH), 134.3, 133.4 (CH), 132.0 (CH), 131.0 (CH), 130.4, 129.7 (CH), 129.1,


128.8, 128.6 (CH), 53.7 (CH<sub>3</sub>). HRMS: Found:  $m/z$  342.0539. Calcd for C<sub>18</sub>H<sub>13</sub>ClNO<sub>4</sub>: (M + H)<sup>+</sup> 342.0533.

**Methyl 5-hydroxy-4-(3-nitro-phenyl)-1-oxo-2,5-dihydro-1H-benzo[c]azepine-3-carboxylate (3h).**




Brown solid. mp 138–140 °C. IR (KBr):  $\tilde{\nu}$  = 1737, 1639, 1527, 1346, 1199, 1113, 1005, 750, 557 cm<sup>-1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  8.23 (d,  $J$  = 8.0 Hz, 1H), 8.10 (s, 1H), 8.00 (d,  $J$  = 7.6 Hz, 1H), 7.93 (brs, 1H), 7.63 (m, 1H), 7.55–7.48 (m, 3H), 7.39 (d,  $J$  = 8.0 Hz, 1H), 5.76 (s, 1H), 3.54 (s, 3H).

**Methyl 4-(3-nitro-phenyl)-1,5-dioxo-2,5-dihydro-1H-benzo[c]azepine-3-carboxylate (18).**




White solid. mp 224 °C. IR (KBr):  $\tilde{\nu}$  = 1744, 1716, 1618, 1400, 1022, 722 cm<sup>-1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  8.72 (s, 1H), 8.40 (d,  $J$  = 7.2 Hz, 1H), 8.24 (d,  $J$  = 7.2 Hz, 1H), 8.10 (s, 1H), 7.81 (m, 3H), 7.57 (m, 2H), 3.58 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$  190.8, 165.7, 164.1, 148.1, 139.2, 137.6, 136.0 (CH), 134.6 (CH), 133.7 (CH), 132.3 (CH), 131.0, 130.6 (CH), 129.1 (CH), 127.2, 124.8 (CH), 123.2 (CH), 54.0 (CH<sub>3</sub>) [N.B. one quaternary C is missing].

**Methyl 5-Hydroxy-4-(6-methoxy-pyridin-3-yl)-1-oxo-2,5-dihydro-1*H*-benzo[*c*]azepine-3-carboxylate (3i).**




Yellow solid. mp 123–124°C. IR (KBr):  $\tilde{\nu}$  = 1716, 1653, 1315, 1284, 1022, 668  $\text{cm}^{-1}$ .  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  8.11 (s, 1H), 7.95 (d,  $J$  = 7.2 Hz, 1H), 7.84 (s, 1H), 7.57 (t,  $J$  = 7.2 Hz, 1H), 7.45–7.39 (m, 3H), 6.79 (d,  $J$  = 8.4 Hz, 1H), 5.66 (s, 1H), 3.99 (s, 3H), 3.58 (s, 3H).

**Methyl 4-(6-methoxy-pyridin-3-yl)-1,5-dioxo-2,5-dihydro-1*H*-benzo[*c*]azepine-3-carboxylate (19).**




White solid. mp 190–193°C. IR (KBr):  $\tilde{\nu}$  = 1740, 1707, 1636, 1440, 722  $\text{cm}^{-1}$ .  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  8.72 (s, 1H), 8.36 (d,  $J$  = 7.6 Hz, 1H), 7.96 (s, 1H), 7.78 (m, 3H), 7.55 (d,  $J$  = 7.6 Hz, 1H), 6.78 (d,  $J$  = 8.0 Hz, 1H), 3.96 (s, 3H), 3.62 (s, 3H).  $^{13}\text{C}$  NMR (100 MHz,  $d_6$ -Acetone):  $\delta$  191.2, 166.7, 165.3, 164.6, 148.1 (CH), 141.8 (CH), 140.0, 135.6, 134.9 (CH), 133.9 (CH), 132.7 (CH), 130.6 (CH), 130.5, 125.9, 110.7 (CH), 79.3, 53.7 ( $\text{CH}_3$ ), 53.5 ( $\text{CH}_3$ ).

**11-hydroxy-2,3,5,11-tetrahydro-1*H*-dibenzo[*b,e*]azepine-4,6-dione (3j).**




Colorless crystal. mp  $>250$  °C. IR (KBr):  $\tilde{\nu} = 1717, 1636, 1362, 1118, 750$   $\text{cm}^{-1}$ .  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  8.09 (brs, 1H), 7.90 (d,  $J = 7.6$  Hz, 1H), 7.59 (d,  $J = 4.0$  Hz, 2H), 7.40 (t,  $J = 4.0$  Hz, 1H), 5.33 (s, 1H), 2.65 (s, 2H), 2.51–2.42 (m, 2H), 2.04–2.02 (m, 1H), 1.79–1.7 (m, 1H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  193.1, 168.9, 148.7, 143.2, 133.1 (CH), 130.5 (CH), 128.8, 128.0 (CH), 127.4, 122.4 (CH), 69.5 (CH), 36.35 ( $\text{CH}_2$ ), 23.72 ( $\text{CH}_2$ ), 21.4 ( $\text{CH}_2$ ).

**Methyl 8-methoxy-1,5-dioxo-2,5-dihydro-1H-benzo[c]azepine-3-carboxylate (20).**



White solid. mp 179–182 °C. IR (KBr):  $\tilde{\nu} = 1727, 1707, 1608, 1448, 1243, 1150, 725$   $\text{cm}^{-1}$ .  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  8.95 (brs, 1H), 8.29 (d,  $J = 8.8$  Hz, 1H), 8.01 (d,  $J = 2.8$  Hz, 1H), 7.30 (dd,  $J = 9.0$  Hz, 2.6, 1H), 6.89 (s, 1H), 3.99 (s, 3H), 3.97 (s, 3H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  186.0, 165.1, 164.1, 163.9, 133.7 (CH), 132.1, 130.7, 130.4, 121.8 (CH), 115.9 (CH), 115.0 (CH), 56.1 ( $\text{CH}_3$ ), 54.7 ( $\text{CH}_3$ ).


**Methyl 5-hydroxy-7,8-dimethoxy-1-oxo-2,5-dihydro-1H-benzo[c]azepine-3-carboxylate (3l).**



White crystalline solid. mp 120–122 °C. IR (KBr):  $\tilde{\nu} = 1718, 1636, 1266, 1130, 766$   $\text{cm}^{-1}$ .  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.93 (brs, 1H), 7.46 (s, 1H), 7.10 (s, 1H), 6.67 (d,  $J = 5.2$  Hz, 1H),


5.46 (d,  $J = 4.8$  Hz, 1H), 3.97 (s, 3H), 3.92 (s, 3H), 3.82 (s, 3H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  167.8, 163.5, 153.2, 148.5, 137.1, 128.3 (CH), 125.7, 120.9, 113.4 (CH), 105.0 (CH), 68.1 (CH), 56.4 (2 X  $\text{CH}_3$ ), 53.2 ( $\text{CH}_3$ ).

**Methyl 5,9-dioxo-6,9-dihydro-5H-1,3-dioxo-6-aza-cyclohepta[f]indene-7-carboxylate (21).**




White solid. mp  $>250$  °C. IR (KBr):  $\tilde{\nu} = 1726, 1705, 1629, 1400, 1330, 772$   $\text{cm}^{-1}$ .  $^1\text{H}$  NMR (400 MHz,  $\text{d}_6$ -DMSO)  $\delta$  10.14 (brs, 1H), 7.80 (s, 1H), 7.56 (s, 1H), 6.53 (s, 1H), 6.34 (s, 2H), 3.93 (s, 3H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{d}_6$ -DMSO):  $\delta$  184.7, 164.2, 163.4, 152.5, 152.1, 134.0, 132.8, 127.2, 112.8 (CH), 110.4 (CH), 107.7 (CH), 103.5 ( $\text{CH}_2$ ), 54.0 ( $\text{CH}_3$ ).

**Methyl 5,9-dioxo-8,9-dihydro-5H-pyrido[2,3-c]azepine-7-carboxylate (22).**



White solid. mp  $192$  °C. IR (KBr):  $\tilde{\nu} = 1733, 1707, 1634, 1448, 1150, 1030, 728$   $\text{cm}^{-1}$ .  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  9.12 (brs, 1H), 9.02 (s, 1H), 8.87 (d,  $J = 8.0$  Hz, 1H), 7.75 (brs, 1H), 7.03 (s, 1H), 4.01 (s, 3H).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  185.6, 164.0, 163.7, 155.3 (CH), 151.3, 142.2 (CH), 131.3, 127.5 (CH), 114.1 (CH), 54.9 ( $\text{CH}_3$ ) [N.B. one quaternary C is missing].

**Methyl 2-azido-3-(6-methoxy-pyridin-3-yl)-acrylate (1i).**




Yellow solid. mp 78–80 °C. IR (KBr):  $\tilde{\nu}$  = 2127, 1710, 1631, 1438, 1256, 1025, 772 cm<sup>-1</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.40 (d, *J* = 2.0 Hz, 1H), 8.26 (dd, *J* = 8.8 Hz, 2.0 Hz, 1H), 6.82 (s, 1H), 6.76 (d, *J* = 9.2 Hz, 1H), 4.02 (s, 3H), 3.92 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$  164.4, 164.0, 150.2 (CH), 139.7 (CH), 124.9, 123.2, 122.3 (CH), 111.0 (CH), 53.9 (CH<sub>3</sub>), 53.1 (CH<sub>3</sub>).


## 7. References:


1. (a) S. K. Ghosh, R. Verma, U. Ghosh and V. R. Mamdapur, *Bull. Chem. Soc. Jpn*, 1996, **69**, 1705; (b) T. M. V. D. Pinho e Melo, A. L. Cardoso, C. S. B. Gomes and , A. M. A. Rocha Gonsalves, *Tetrahedron Lett.*, 2003, **44**, 6313.
2. V. Nair and T. G. George, *Tetrahedron Lett.*, 2000, **41**, 3199.
3. B. J. Stokes, H. Dong, B. E. Leslie, A. L. Pumphrey and T. G. Driver, *J. Am. Chem. Soc.*, 2007, **129**, 7500.
4. D. Knittel, *Synthesis*, 1985, 186.
5. P. Roy, M. Boisvert and Y. Leblanc, *Organic Syntheses*, 2007, **84**, 262.
6. B. B. Snider and H. Lin, *Synth. Commun.*, 1998, **28**, 1913.
7. R. V. Hoffman and B. S. Severns, *J. Org. Chem.*, 1996, **61**, 5567.
8. M. A. Brimble and C. V. Burgess, *Synthesis*, 2007, 754.
9. M. A. A. Meziane, S. Royer and J. P. Bazureau, *Tetrahedron Lett.*, 2001, **42**, 1017.
10. A. K. Sinhababu and R. T. Borhardt, *J. Org. Chem.*, 1983, **48**, 2356.
11. S. C. Karcher and S. A. Laufer, *J. Med. Chem.*, 2009, **52**, 1778.



## 8. NMR Spectra of the new compounds:


































































## 9. X-ray crystal structure:



**Figure 1.** ORTEP projection of the Methyl 4-methyl-1,5-dioxo-2,5-dihydro-1H-benzo[c]azepine-3-carboxylate (**12**)



**Figure 2.** ORTEP projection of the Methyl 5-hydroxy-1-oxo-4-phenyl-2,5-dihydro-1*H*-benzo[*c*]azepine-3-carboxylate (**3d**)



**Figure 3.** ORTEP projection of the methyl 4-(4-chloro-phenyl)-5-hydroxy-1-oxo-2,5-dihydro-1*H*-benzo[*c*]azepine-3-carboxylate (**3g**)